-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – CBL-514 in Cellulite
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - CBL-514 in Cellulite report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. CBL-514 in Cellulite Drug Details: CBL-514 is under development for the treatment to...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – CBL-514 in Adiposis Dolorosa (Dercum’s Disease or Anders Disease)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - CBL-514 in Adiposis Dolorosa (Dercum's Disease or Anders Disease) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. CBL-514 in Adiposis Dolorosa (Dercum's Disease or...
-
Product Insights
NewPTA Peripheral DCB Catheters Pipeline by Development Stages, Segments, Region and Countries, Regulatory Path and Key Companies
PTA Peripheral DCB Catheters Pipeline Market Report Overview A PTA Peripheral DCB Catheter is a drug-coated percutaneous transluminal angioplasty (PTA) balloon intended to prevent restenosis or restenosis of the peripheral arteries. PTA Peripheral DCB catheters provide fast, short-term, homogenous, local drug delivery to the vessel wall while preserving the anatomy of the vessel, promoting enhanced vessel healing, and reducing the need for prolonged dual antiplatelet therapy. They can be used to treat native and in-stent restenosis (ISR), bifurcations, small vessels,...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – AB-08 in Breast Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. AB-08 in Breast Cancer Drug Details: AB-08 is under development for the treatment of breast,...
-
Product Insights
Short Bowel Syndrome – Drugs In Development, 2023
Global Markets Direct’s, ‘Short Bowel Syndrome - Drugs In Development, 2023’, provides an overview of the Short Bowel Syndrome pipeline landscape. The report provides comprehensive information on the therapeutics under development for Short Bowel Syndrome, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...
-
Product Insights
Sickle Cell Disease – Drugs In Development, 2023
Global Markets Direct’s, ‘Sickle Cell Disease - Drugs In Development, 2023’, provides an overview of the Sickle Cell Disease pipeline landscape. The report provides comprehensive information on the therapeutics under development for Sickle Cell Disease, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...
-
Product Insights
Non Alcoholic Fatty Liver Disease (NAFLD) – Drugs In Development, 2023
Global Markets Direct’s, ‘Non Alcoholic Fatty Liver Disease (NAFLD) - Drugs In Development, 2023’, provides an overview of the Non Alcoholic Fatty Liver Disease (NAFLD) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Non Alcoholic Fatty Liver Disease (NAFLD), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – CBL-514 in Benign Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - CBL-514 in Benign Tumor report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. CBL-514 in Benign Tumor Drug Details: CBL-514 is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – CBL-514 in Obesity
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - CBL-514 in Obesity report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. CBL-514 in Obesity Drug Details: CBL-514 is under development for the treatment...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – SRN-001 in Idiopathic Pulmonary Fibrosis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - SRN-001 in Idiopathic Pulmonary Fibrosis report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. SRN-001 in Idiopathic Pulmonary Fibrosis Drug Details: SRN-001 is under development for...